Six pharmas employing Epic Sciences’ circulating tumor cell technology

Wednesday, August 15, 2012 10:38 AM

Epic Sciences, a privately held cancer diagnostics company of La Jolla, Calif., has established collaborations with six pharmaceutical partners employing Epic’s proprietary Circulating Tumor Cell (“CTC”) technology.

The partners include two of the top four pharmaceutical companies worldwide. In total, the collaborations include 12 clinical trials involving over 40 distinct projects measuring 18 different protein or genomic tumor markers on CTCs. The clinical trials include sites in the U.S., Europe and Asia, with over 1,500 patients and 2,500 clinical samples in prostate, lung, breast, pancreatic and ovarian cancers.

These partnerships leverage Epic’s platform to identify and characterize rare cells in fluids. Most CTC technologies employ a physical enrichment strategy based on a few markers thought to be present on the majority of cancer cells. Because cancer cells are heterogeneous, Epic chose a different path which physically retains all of the cells and identifies the CTCs using multi-parametric analysis in a “no cells left behind” strategy.

“Given that we have been operating in stealth mode, Epic has been pleased by the extraordinary level of interest and clinical deal flow around our CTC detection and characterization platform,” said Dr. David Nelson, president and CEO of Epic Sciences. “By using Epic to molecularly characterize CTCs, our pharmaceutical partners are looking to improve the success rate, decrease the cost, and expedite commercial launch of their targeted therapies. Payers are also expected to gain by achieving better health economics as care evolves to provide the right drug to the right patient at the right time.

Nelson added, “Ultimately, of course, we hope that the biggest beneficiaries will be all of the patients whose individual outcomes are improved by personalized medicine guided by Epic’s diagnostic products.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs